The Indian API market is undergoing a major transformation driven by China+1 sourcing strategies, PLI schemes, and growing domestic demand. Explore the key trends shaping the API market in India.
India's Growing Role in the Global API Market
India currently accounts for approximately 20% of global API volume by quantity and supplies to over 200 countries. With over 500 API manufacturing facilities approved by global regulatory agencies including the US FDA, EMA, WHO, and TGA (Australia), India is positioned as a critical node in the global pharmaceutical supply chain.
The domestic API market is valued at approximately USD 11–12 billion and is projected to grow at a CAGR of 7–9% through 2027, driven by multiple structural tailwinds.
Key Market Drivers
1. China+1 Sourcing Strategy
The COVID-19 pandemic exposed the risks of concentrated pharmaceutical supply chains, particularly India's dependence on China for key starting materials (KSMs) and APIs. Global pharmaceutical companies are now actively diversifying their API supply chains by qualifying Indian manufacturers as alternative or primary sources.
This "China+1" trend has directly benefited Indian API manufacturers and distributors, leading to increased capacity investments and new long-term supply agreements.
2. Production Linked Incentive (PLI) Scheme
The Indian government launched the PLI scheme for pharmaceutical APIs with an outlay of ₹6,940 crore. This incentivises domestic production of 53 critical APIs (including vitamins, antibiotics, and cardiovascular molecules) where India was import-dependent, primarily on China.
PLI has catalysed new investments in API manufacturing across states including Andhra Pradesh, Gujarat, Maharashtra, and Tamil Nadu.
3. Rising Domestic Formulation Demand
India's pharmaceutical formulation industry continues to grow at 8–10% annually, driven by:
- Rising disease burden (diabetes, cardiovascular diseases, cancer)
- Increased health insurance penetration (Ayushman Bharat)
- Growing middle class with higher healthcare spending
- Expansion of generic drug access
This directly translates to increased API consumption domestically.
4. Export Market Expansion
Indian API manufacturers are qualifying their products in regulated markets (US, EU, Japan) and semi-regulated markets (Africa, Southeast Asia, Latin America) simultaneously. The value of API exports from India crossed USD 7 billion in 2023.
Key API Categories Driving Growth
| API Category | Growth Driver |
|---|---|
| Cardiovascular APIs | Ageing population, lifestyle diseases |
| Antidiabetic APIs | Diabetes epidemic, new molecules (SGLT2, GLP-1) |
| Oncology APIs | Increased cancer incidence, biosimilar growth |
| Antibiotic APIs | Pandemic preparedness, resistance management |
| Respiratory APIs | Post-COVID respiratory disease burden |
Challenges Facing the API Sector
- API price volatility driven by raw material (KSM) fluctuations
- Regulatory compliance costs as market access requirements tighten
- Environmental regulations — pharmaceutical effluent management
- Skilled workforce gaps in API manufacturing and QC
- Logistics costs impacting competitiveness
Opportunities for API Distributors
For pharmaceutical distributors and traders, the evolving API landscape presents clear opportunities:
1. Stocking high-demand generics — metformin, atorvastatin, telmisartan
2. Specialty API distribution — oncology, immunology APIs
3. Export-oriented supply — supporting Indian formulation exporters
4. KSM and intermediate supply — catering to API manufacturers
5. Value-added services — regulatory documentation support, technical expertise
The Role of Tamil Nadu and Chennai
Tamil Nadu hosts a vibrant pharmaceutical manufacturing cluster, with companies ranging from small-scale formulators to large API manufacturers. Chennai, as the commercial and logistics hub, plays a critical role in API and bulk drug distribution across South India.
Chennai Drugs and Chemicals is well-positioned to support this growing ecosystem with a comprehensive product range, regulatory-compliant supply chain, and expert team.
Conclusion
The Indian API market is at an inflection point. China+1 strategies, PLI investments, and domestic demand growth create a favourable environment for API manufacturers, distributors, and the broader pharmaceutical ecosystem. Companies that invest in quality, compliance, and supply chain resilience will capture the largest share of this opportunity.